Hsu, Hung-Lun http://orcid.org/0000-0003-1284-4182
Brown, Alexander
Loveland, Anna B. http://orcid.org/0000-0001-9172-7747
Lotun, Anoushka
Xu, Meiyu
Luo, Li
Xu, Guangchao
Li, Jia
Ren, Lingzhi
Su, Qin
Gessler, Dominic J.
Wei, Yuquan
Tai, Phillip W. L. http://orcid.org/0000-0001-7409-8344
Korostelev, Andrei A. http://orcid.org/0000-0003-1588-717X
Gao, Guangping http://orcid.org/0000-0003-0097-9012
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01HL131471, UG3HL147367)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (P01HD080642)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI121135)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Defense (W81XWH-17-1-0212)
Bill and Melinda Gates Foundation (OPP1132169)
Article History
Received: 8 September 2019
Accepted: 27 May 2020
First Online: 30 June 2020
Competing interests
: G.G. is a scientific co-founder of Voyager Therapeutics and holds equity in the company. G.G. is an inventor on patents with potential royalties licensed to Voyager Therapeutics and other biopharmaceutical companies. G.G. and D.J.G. are scientific co-founders of Aspa Therapeutics Inc., and hold equity in the company. G.G. and D.J.G. are inventors on patents with potential royalties licensed to Aspa Therapeutics Inc., and other biopharmaceutical companies. Remaining authors declare no competing interests.